KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBT (2016 - 2025)

Alnylam Pharmaceuticals' EBT history spans 16 years, with the latest figure at $86.3 million for Q4 2025.

  • For Q4 2025, EBT rose 144.47% year-over-year to $86.3 million; the TTM value through Dec 2025 reached $329.1 million, up 187.21%, while the annual FY2025 figure was $323.2 million, 185.63% up from the prior year.
  • EBT reached $86.3 million in Q4 2025 per ALNY's latest filing, down from $280.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $280.6 million in Q3 2025 to a low of -$405.9 million in Q3 2022.
  • Average EBT over 5 years is -$123.0 million, with a median of -$180.3 million recorded in 2021.
  • The largest YoY upside for EBT was 358.2% in 2025 against a maximum downside of 216.63% in 2025.
  • A 5-year view of EBT shows it stood at -$260.3 million in 2021, then increased by 20.47% to -$207.0 million in 2022, then surged by 33.49% to -$137.7 million in 2023, then tumbled by 40.87% to -$194.0 million in 2024, then soared by 144.47% to $86.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's EBT are $86.3 million (Q4 2025), $280.6 million (Q3 2025), and -$35.4 million (Q2 2025).